RecruitingPHASE2, PHASE3NCT04147286

Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion

Studying Tuberculosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Cape Town
Principal Investigator
Friedrich Thienemann, MD
University of Cape Town
Intervention
Atorvastatin 40mg(drug)
Enrollment
220 target
Eligibility
18-65 years · All sexes
Timeline
20202027

Study locations (1)

Collaborators

University of Zurich · University of Namibia · University of Bern · University of Stellenbosch

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04147286 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis

← Back to all trials